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Utilization of cardiac monitoring tests in women 
with nonmetastatic breast cancer treated with 
trastuzumab
Trastuzumab is one of the best known exam‑
ples of personalized medicine. It targets 
HER‑2‑positive breast cancer and significantly 
reduces breast‑cancer mortality in women who 
are HER‑2 positive [1–4]. However, this drug 
can cause left ventricular dysfunction, a poten‑
tially serious side effect, by interfering with EGF 
receptor‑2‑mediated cell signaling, an important 
pathway for growth and protection of cardiomy‑
ocytes [1–5]. About 10% of trastuzumab recipi‑
ents show a decline in left ventricular ejection 
fraction (LVEF) and 1–4% develop symptoms 
of systolic heart failure [1–3]. While trastuzumab‑
related left ventricular dysfunction can be 
reversible or treatable, some patients experience 
long‑term adverse effects from the drug [6]. 
Trastuzumab product labeling and profes‑
sional guidelines recommend monitoring car‑
diac function before trastuzumab‑based ther‑
apy in order to avoid use of the drug among 
patients at elevated cardiac risk, and regularly 
every 3–4 months during therapy to detect left 
ventricular dysfunction early with the hope of 
stopping therapy before it becomes symptom‑
atic [7,8,101]. Both radionuclide ventriculography 
(RVG; also known as multigated acquisition 
scan or MUGA scan) and echocardiography 
are commonly used to monitor left ventricular 
function. RVG has a high reproducibility and 
low intra‑ and inter‑observer variability, but it 
exposes the patient to radiation and is expen‑
sive [9,10]. Echocardiography is easy to perform 
and does not expose the patient to radiation, but 
often requires the involvement of a cardiologist 
[10]. Neither the product labeling nor profes‑
sional guidelines recommend a specific cardiac 
monitoring test. 
Little is known about the use of cardiac moni‑
toring in routine clinical practice, and more 
specifically about whether patient, diagnosis 
or health system factors are associated with the 
frequency or type of testing. Our objective was 
to use linked administrative claims and chart 
review data from a large national health plan 
to assess the utilization and predictors of car‑
diac monitoring among women with nonmeta‑
static breast cancer receiving trastuzumab‑based 
chemotherapy. 
Patients & methods
 Data sources & study sample
We utilized administrative claims data from a 
large national health plan, the name of which 
we cannot provide because of our data‑use 
agreement. The data source and study sam‑
ple, including identification of incident breast 
Aims: Trastuzumab, one of the best known examples of personalized medicine, requires regular cardiac 
monitoring because it can cause heart failure. We aimed to assess the utilization of cardiac monitoring in 
women with nonmetastatic breast cancer receiving trastuzumab-based chemotherapy in routine clinical 
practice. Patients & methods: The medical records of women continuously enrolled in a large national 
health insurance plan who were diagnosed with nonmetastatic breast cancer and treated with trastuzumab 
from 2006 to 2008 were reviewed (n = 109). The primary outcome variables were the use and type of 
cardiac monitoring testing before and during trastuzumab therapy. An exploratory multivariable logistic 
regression ana lysis was performed to identify predictors for receiving cardiac monitoring both at baseline 
and during trastuzumab treatment. Results: Monitoring both before and during therapy was less common 
(62%), although 74% had cardiac monitoring before therapy and 80% had at least one test during therapy. 
Radionuclide ventriculogram was utilized more often than echocardiography (48 vs 42%). Only the use 
of anthracycline (odds ratio: 2.39; 95% CI: 1.01–5.71) was significantly associated with use of a cardiac 
monitoring both at baseline and during trastuzumab treatment. Conclusion: The use of cardiac monitoring 
testing was variable and opportunities to improve quality and reduce cost are evident. These results have 
clinical implications for other personalized medicine interventions requiring regular laboratory monitoring.
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cancer cases, have been previously described [11]. 
Briefly, the data set included 7575 women with 
incident breast cancer diagnosed between 2006 
and 2008. The claim data set contained medi‑
cal and pharmacy claims 6 months before, and 
up to 2 years after the date of cancer diagnosis. 
Of 7575 women, initially 2100 subjects were 
randomly selected. Of these 2100 subjects, 700 
subjects whose primary oncologists or surgeons 
were willing to have their charts reviewed were 
selected for chart review to collect data such as 
demographic information, past medical history, 
pathology and laboratory test results, including 
dates, types and results of cardiac monitoring 
tests. A Charlson comorbidity index was con‑
structed based on the patient’s medical history 
[12]. For this ana lysis, we included women aged 
30 to 64 years with nonmetastatic breast cancer 
who were treated with trastuzumab (n = 109). 
Women who had a disease requiring regular car‑
diac monitoring (i.e., cardiac valvular diseases, 
pulmonary arterial hypertension, congenital 
heart diseases, cardiomyopathy, endocarditis or 
heart failure) were excluded (n = 1). 
 Trastuzumab treatment, cardiac 
monitoring & primary outcomes
Duration of trastuzumab treatment was defined 
as the number of days between the starting and 
last dates of trastuzumab administration. Base‑
line (i.e., before trastuzumab) ‘cardiac monitor‑
ing’ was defined as any test within 180 days prior 
to the first trastuzumab administration date. 
During therapy, ‘monitoring’ was defined as any 
test from the first trastuzumab administration to 
the last available claim. We identified patients 
who had baseline and/or during‑therapy moni‑
toring, and patients who had monitoring during 
therapy at least every 90 days. We chose every 
90 days as the study interval because it is recom‑
mended by many guidelines [7,101]. We described 
the type of cardiac monitoring test used: echo‑
cardiography, RVG, or both. We also described 
the rate of significant left ventricular dysfunction 
during trastuzumab treatment, defined as LVEF 
≤40% or both LVEF <55% and an LVEF drop 
>10% from baseline.
 Statistical ana lysis
We conducted bivariate analyses to examine the 
association between potentially important fac‑
tors and cardiac monitoring. We hypothesized 
that the following patient and clinical character‑
istics might be associated with the use of cardiac 
monitoring: age, race, region, grade, Charlson 
index, use of an anthracycline chemotherapy 
agent, receipt of radiation therapy, type of breast 
surgery (mastectomy or lumpectomy) and cancer 
stage. Exploratory multivariate logistic regression 
analyses were performed to assess the relationship 
between these variables and the use of a cardiac 
monitoring both before and during treatment. 
Only variables with a p‑value <0.2 on bivariate 
ana lysis were entered into multivariate ana lysis. 
p‑values were two‑tailed and considered statisti‑
cally significant if they were <0.05. All analyses 
were performed using SAS 9.1 (Cary, NC, USA).
Results
The median age was 50 (range: 30–63; Table 1). 
More than half of the study population was 
white, resided in the southern part of the USA, 
and had stage II breast cancer at the time of diag‑
nosis. Few women had a pre‑existing cardiovas‑
cular comorbid condition (two women with cere‑
brovascular disease and six women with diabetes 
mellitus). Over 60% received radiation therapy 
and anthracycline‑based chemotherapy before 
starting trastuzumab. The median duration of 
trastuzumab treatment was 358 days (range: 
98–805 days). 
The number of cardiac monitoring tests per‑
formed ranged from 0–10, with a median of 3. 
A total of 92% received a cardiac test either at 
baseline or during trastuzumab treatment. At 
baseline, 74% had cardiac monitoring and the 
median LVEF was 62% (range: 45–78). Trastu‑
zumab treatment was started a median of 21 days 
(range: 0–153 days) after the baseline cardiac 
monitoring test. During trastuzumab treatment, 
80% received a test at least once, but only 28% 
had testing once every 90 days. About 62% of 
the women received a cardiac monitoring test at 
baseline and at least once during trastuzumab 
treatment; only 21% had testing at baseline 
and at least every 90 days during trastuzumab 
treatment. 
Of the 100 women who had at least one cardiac 
monitoring test, 21% had only one test (Table 2). 
Type of testing was only echocardio graphy for 
24% of the cohort, only RVG for 32% and both 
for 44%. Of 297 cardiac monitoring tests, RVG 
was utilized more often than echocardiography 
(48 vs 42%), especially at baseline (RVG, 62.5% 
vs echocardiography, 37.5%) (Table 3). 
In the bivariate ana lysis, tumor stage and 
receipt of anthracycline were significantly associ‑
ated with use of cardiac monitoring, both at base‑
line and during trastuzumab treatment: (69% in 
the subjects with stage II or III vs 49% in the 
subjects with stage I, p = 0.04; 70% in the subjects 
who used an anthracycline chemo‑agent vs 46% 
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in the subjects who did not use an anthracycline 
chemoagent, p = 0.014). On multivariate logistic 
regression ana lysis, only use of anthracycline (odds 
ratio: 2.39; 95% CI: 1.01–5.71) was significantly 
associated with use of cardiac monitoring both at 
baseline and during trastuzumab treatment.
Five women developed an LVEF ≤40%, or 
an LVEF <55% and a LVEF drop >10% from 
baseline, during trastuzumab treatment. Of 
these, four (80%) had trastuzumab treatment 
interrupted as a result of the identified left ven‑
tricular dysfunction, but subsequently resumed 
treatment. All four had cardiac monitoring before 
resuming trastuzumab therapy.
Discussion
Using chart review and national claims data for 
patients with nonmetastatic breast cancer treated 
with trastuzumab‑based chemotherapy, we found 
variable use of cardiac monitoring. While most 
patients had some form of cardiac testing, a sub‑
stantial minority had no baseline testing (14%) 
or no testing during therapy (13%). While 92% 
had testing before or during trastuzumab‑based 
therapy, only 62% had testing both at baseline 
and during trastuzumab therapy, and only 21% 
had testing before and at least once every 90 days 
during therapy. 
Few other studies have evaluated the use of 
cardiac monitoring in routine clinical practice. 
Subar et al. identified a 67% rate of baseline car‑
diac monitoring, an 88% rate of testing before 
or during therapy and a 16% rate of testing 
according to the standard monitoring schedule 
by using administrative data from 664 patients 
with nonmetastatic breast cancer treated with 
trastuzumab in 2007 [13]. While it is reassuring 
that our findings are similar, it is disappointing 
that both studies identify a subset of patients who 
do not have testing. Our findings have clinical 
implications for other personalized medicine 
interventions, such as ivacaftor and crizotinib, 
because their successful use in clinical practice 
may depend on regular laboratory monitoring. 
Using exploratory multivariable ana lysis, we 
found a positive relationship between cardiac 
monitoring and receipt of anthracycline‑based 
chemotherapy. The anthracycline‑related finding 
is not surprising, considering that anthracycline 
chemotherapy agents cause cardiac toxicity, and 
is consistent with the result of the study by Subar 
et al. [13]. To our surprise, age, region and race 
were not associated with cardiac monitoring, 
possibly due to the small sample size. The study 
by Subar et al. was not able to evaluate the rela‑
tionship between detailed patient, diagnosis and 
Table 1. Baseline characteristics of the study population (n = 109).
Characteristics n (%)
Age at diagnosis
30–49 years (%) 54 (49.5)
Race
African–Americans (%) 5 (4.6)
Asian (%) 5 (4.6) 
White (%) 56 (51.4)
Hispanic (%) 2 (1.8)
Unknown (%) 41 (37.6)
Geographical region
North east 8 (7.3)
Midwest 22 (20.2)
South 67 (61.5)
West 12 (11.1)
Stage
I 35 (32.1)
II 57 (52.3)
III 17 (15.6)
Tumor size
<1.0 cm 11 (10.1)
1.0–3.0 cm 77 (65.7)
≥3.1 cm 13 (11.9)
Unknown 8 (7.3)
Lymph node involvement
Yes 52 (47.7)
Unknown 2 (1.8) 
Grade
Good 1 (1.0)
Moderate 28 (25.7)
Poor 76 (69.7)
Unknown 4 (3.7)
Previous medical history
Heart failure 0 (0)
Diabetes mellitus 6 (5.5)
Charlson comorbidity index
0 94 (86.2)
1+ 15 (13.8)
Surgery
Lumpectomy 50 (45.9)
Mastectomy 59 (54.1)
Radiation 68 (62.4)
Anthracycline-containing regimen 74 (67.9)
Hormonal therapy 66 (60.5)
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treatment characteristics and the use of cardiac 
monitoring because it was based only on claim 
data [13]. 
There may be several reasons for the vari‑
able utilization of cardiac monitoring. First, 
the clinical trials that established trastuzumab 
as an effective component in the treatment of 
nonmetastatic breast cancer used different car‑
diac monitoring schedules [1,13,14]. Second, while 
the trastuzumab product labeling and several 
guidelines describe who, how and when to test, 
they provide inconsistent advice regarding the 
frequency of testing and the specific LVEF value 
or change from baseline that should prompt an 
alteration in therapy [7,8,101]. For example, the 
product labeling recommends monitoring car‑
diac function every 3 months while on therapy, 
and discontinuing trastuzumab if the LVEF 
drops ≥16% from the baseline or the LVEF 
becomes below institutional limits of normal 
values and drops ≥10% from the baseline [101]. 
On the other hand, the UK National Cancer 
Research Institute recommends monitoring 
cardiac function at 4 and 8 months while on 
therapy and interrupting trastuzumab treat‑
ment if the LVEF is ≤40% [8]. Finally, the lack 
of data on clinical utility of cardiac monitoring 
in this population contributes to the inconsistent 
guideline recommendations and variable utiliza‑
tion of cardiac monitoring in our study. Thus, a 
study rigorously evaluating the need for and fre‑
quency of cardiac monitoring in this population 
is needed. 
Analysis of the types of tests ordered as 
part of cardiac monitoring before and during 
trastuzumab‑based therapy found that RVG 
was used more often than echocardiography. 
This difference was more prominent at baseline 
than during treatment, though this could reflect 
sampling bias for the subset of patients who con‑
tinued on trastuzumab for a longer period of 
time. We are unaware of another study describ‑
ing utilization patterns of echocardiography and 
RVG among women with nonmetastatic breast 
cancer receiving trastuzumab. The two testing 
modalities offer similar results and guidelines 
tend to avoid recommending one over the other. 
Choice of test could be influenced by cost, ease 
of scheduling, and/or the availability of the 
specialist who conducts and interprets the test 
(radiologist vs cardiologist). Given the substan‑
tial cost difference (US$248.13 per RVG vs 
US$148.40 per echocardiogram in 2012), the 
choice of testing modality could have significant 
policy implications [102].
Five patients (4.5% of our study sample) devel‑
oped a LVEF ≤40% or both LVEF <55% and a 
LVEF drop >10% from baseline during trastu‑
zumab therapy, and only one did not recover her 
LVEF. These rates of asymptomatic decline in 
ejection fraction and persistent abnormal cardiac 
function are consistent with previous estimates 
of the risks associated with trastuzumab‑based 
therapy and of the chances that the cardiac‑
related adverse effects of trastuzumab can be 
reversed [1]. It is reassuring to confirm these find‑
ings in a routine care cohort, although, given the 
small sample size and relatively short duration of 
follow‑up in this study, caution should be taken 
when interpreting these results. 
Table 2. Utilization of echocardiography and radionuclide 
ventriculography at individual level (n = 100).
Number of 
cardiac 
monitoring tests
Type of cardiac monitoring 
test
n (%)
One Total number of subjects 21
Echo 4 (19.0)
RVG 9 (42.9)
Unknown 8 (38.1)
Multiple times Total 79
Echo only 20 (25.3)
RVG only 23 (29.1)
Both Echo and RVG 16 (20.3)
Unknown 20 (25.3)
Combined Number of subjects 100
Echo only 24 (24)
RVG only 32 (32)
Echo: Echocardiography; RVG: Radionuclide ventriculography.
Table 3. Utilization of echocardiography and radionuclide 
ventriculography at test level (n = 297).
Timing of cardiac 
monitoring test
Type of cardiac monitoring 
test
n (%)
At baseline Total 81
Echo 30 (37.5)
RVG 50 (62.5)
Unknown 1 (1.2)
During trastuzumab 
treatment
Total 216
Echo 95 (44.0)
RVG 92 (42.6)
Unknown 29 (13.4)
Combined Number of tests 297
Echo 125 (42.1)
RVG 142 (47.8)
Echo: Echocardiography; RVG: Radionuclide ventriculography.
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Given the lack of research on this topic, our 
study provides useful findings despite several 
limitations. First, the small sample size limits 
our ability to model factors associated with 
the use of cardiac monitoring tests or to fully 
explore how trastuzumab and cardiac monitor‑
ing tests were utilized in patients with trastu‑
zumab‑induced left ventricular dysfunction. 
Second, our results may not be applicable to 
patients >65 years old. Third, our data were col‑
lected between 2006 and 2008, and may not be 
representative of utilization patterns at present. 
Finally, although the combined chart review 
and claims methodology helped identify car‑
diac monitoring tests, patients still could have 
had undocumented tests. 
Conclusion
The utilization of cardiac monitoring among 
patients with nonmetastatic breast cancer receiv‑
ing trastuzumab found many patients received 
testing as recommended, but identified potential 
opportunities for improvement. Some patients 
have no baseline monitoring and some have no 
or infrequent monitoring during therapy. In 
addition, given similar efficacy and variable use 
of RVG and echocardiography, opportunities 
to improve the efficiency of care may also exist. 
Future perspective
In the near future, several strategies may be 
employed to improve quality‑of‑care for patients 
with nonmetastatic breast cancer who receive 
trastuzumab. For example, payers may send 
alerts to any provider who administers trastu‑
zumab in a patient with no claim for cardiac 
monitoring or may require report of ejection 
fraction as part of preauthorization of trastu‑
zumab. In addition, ordering cardiac monitor‑
ing may be included in the assessment of perfor‑
mance of providers who prescribe trastuzumab. 
Because it is currently unclear whether regular 
cardiac monitoring reduces the risk of develop‑
ing heart failure and how often cardiac moni‑
toring should be performed, studies addressing 
these questions should be conducted. Since 
trastuzumab is one of the best known examples 
of personalized medicine, these may help imple‑
ment other personalized medicine interventions 
in clinical practice in the future.
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Executive summary
Background
  Trastuzumab, one of the best known examples of personalized medicine, requires regular cardiac monitoring because it can cause 
heart failure. 
  Trastuzumab product labeling and professional guidelines recommend monitoring cardiac function before trastuzumab-based therapy, 
and every 3–4 months during therapy to detect left ventricular dysfunction early. 
Results
  Despite these recommendations, only 62% of patients had testing both at baseline and during trastuzumab therapy, and only 21% had 
testing before and at least once every 90 days during therapy.
  In addition, a substantial minority had no baseline testing (14%) or no testing during therapy (13%). 
  Radionuclide ventriculography was used more often than echocardiography. Given the substantial cost difference (US$248.13 per 
radionuclide ventriculography vs US$148.40 per echocardiogram in 2012), the choice of testing modality could have significant policy 
implications. 
Conclusion
  Our data suggest potential opportunities to improve quality and efficiency of care in women with nonmetastatic breast cancer 
receiving trastuzumab. 
  Our findings have clinical implications for other personalized medicine interventions, such as ivacaftor and crizotinib because their 
successful use in clinical practice may depend on regular laboratory monitoring.
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